SAN FRANCISCO—Dr Tomasz Beer, said their new data make a good case for using enzalutamide to treat prostate cancer in chemo-naïve patients. He spoke reassuringly about both efficacy and safety.
Tomasz Beer MD, Oregon Health & Science University
“Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study”
Abstract #LBA1^
ASCO 2014 Genitourinary Cancers Symposium
Single cell transcriptome analysis yields details of molecular features that promise to help customise therapy for each individual patient.
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...
Audio Journal of Oncology Podcast Ultrahypofractionated Radiation Just As Effective for Prostate Cancer Play Episode Pause Episode Mute/Unmute...
PHILADELPHIA, USA—For the first time researchers have succeeded in making small number of patients with AIDS more resistant to HIV by infusing them...
STOCKHOLM, SWEDEN—A study in JAMA Anti-coagulation has reported that warfarin could be beneficial for patients with atrial fibrillation (AF) even if...
CINCINNATI, USA—A link has been demonstrated for the first time between prostate cancer and exposure to the synthetic compound bisphenol-A (BPA ) —...